Clinical Trials

The Grand Valley Oncology research department is proud to partner with:

University of Utah
Huntsman Cancer Institute




Clinical Trials Team

Current Open Trials

Breast Cancer:
Polaris: Palbociclib In Hormone Receptor Positive Advanced Breast Cancer: A Prospective Multicenter Non-interventional Study

Breast Cancer Weight Loss Study (BWEL Study)

GU Cancers (Bladder, Urothelial, Kidney, etc.):
Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation

Metastatic Cancers:
Electronic Patient Reporting of Symptoms During Cancer Treatment (PRO-TECT)
*As of 3/6/19 Grand Valley Oncology has reached maximum number of participants for this study. Website will be updated if our site is allowed to enroll additional participants.

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

Leukemia (CLL):
Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia

Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Older Patients With Untreated Chronic Lymphocytic Leukemia

Expanded Access / Compassionate Use:
Please contact the Grand Valley Oncology Clinical Trial Team at 970-644-4460 or to discuss Expanded Access / Compassionate Use programs that may be available.

Click here to learn more about Hunstman Cancer Institute clinical trials.

Information for Sponsors

  • Our current FWA Status can be verified by entering FWA "00024869" (or Colorado West Healthcare System) here.
  • We have created a Site Information Profile Document to assist sponsors in assessing whether or now we may be a good fit for a potential study. Request a copy here.
  • Our research team meets every Tuesday to review potential research studies. Please email your introduction letter and/or synopsis to with an Attn: Research Director.

What are Clinical Trials?

Clinical trials are research studies. The cancer treatments used today came from clinical trials.

There are many different purposes for clinical trials:
  • Some clinical trials evaluate new drugs.
  • Others study new ways to give already approved drugs or new combinations of drugs.
  • Some studies look at new combinations with other treatments such as surgery or radiation.
  • Other studies may be about cancer prevention.
  • Some studies may look at ways to diagnose cancer or ways to make life better for cancer patients.

Carefully conducted clinical trials are the fastest and safest way to find treatments that work. Participation in a clinical trial is 100% voluntary. This means you can withdraw from the study at any time if you or your medical team decide the clinical trial is no longer the best option for you.

How do I participate in a clinical trial with Grand Valley Oncology?

Each clinical trial has patients with a specific type and stage of cancer. Participating in a clinical trial is your decision, however your doctor must first determine if you meet the requirements for the study you are interested in.

In general, you must meet these requirements:
  • The type and extent of your cancer has the same characteristics as the cancer being studied.
  • A doctor has reviewed your general health, and it meets study requirements.
  • We have answered all your questions about clinical trials.
  • You understand the possible benefits and risks of participating.
  • You agree to participate, and you have signed and submitted your informed consent form.

For more in-depth information, click here.

What are the benefits and risks?

As with any treatment option, a clinical trial has possible benefits, as well as drawbacks. You may want to discuss the following issues with your doctor and the people close to you.

Possible benefits:
  • Clinical trials offer high-quality cancer care. If you are in a randomized study and do not receive the new treatment being tested, you will receive the best known standard treatment. This may be as good as, or better than, the new approach.
  • If a new treatment is proven to work and you are receiving it, you may be among the first to benefit.
  • You have the chance to help others and improve cancer treatment.

Possible drawbacks:
  • New treatments under study are not always better than, or even as good as, standard care.
  • New treatments may have side effects that doctors do not expect or that are worse than those of standard treatment.
  • Even if a new treatment has benefits, it may not work for you. Even standard treatments, proven effective for many people, do not help everyone.
  • Health insurance and managed care providers may not cover all patient care costs in a study.

Clinical Trial Phases

Clinical Trial Phases

Grand Valley Oncology offers mostly Phase III studies and some Phase II studies. If Grand Valley Oncology does not offer a clinical trial you are interested in, the clinical trials team can assist in referring you to other facilities that do offer the trial.

Contact Us

If you would like to learn more, please contact the Grand Valley Oncology Clinical Trial Team at (970) 644-4460 or

Conflict of Interest

In accordance with Federal regulations and institutional policy, researchers at CWHS/GVO are required to disclose Significant Financial Interests (SFIs). Additionally, CWHS / GVO is required to post our institutional policy related to Financial Conflict of Interest (FCOI) for researchers. The policy is available here.

Members of the public can request and obtain the following information concerning any SFIs held by senior / key personnel for a Public Health Service funded research project where the SFI is determined to be a Financial Conflict of Interest, as defined by our policy:

  • The researcher’s name
  • The researcher’s title and role with respect to the research project
  • The name of the entity in which the significant financial interest is held
  • Nature of the Significant Financial Interest
  • Approximate dollar value (by dollar range) of the significant financial interest or a statement that the interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

To obtain this information, send an email to: We require the name of the researcher or a description of the records of interest in order to access the information. Please also include the address to which the information shall be sent. Once the request is received, a response will be provided within 5 business days.

Additional information: The National Institutes of Health has published a Frequently Asked Questions Web page to explain new federal regulations pertaining to conflict of interest reporting and records availability. New regulations related to reporting and availability went into effect on August 24, 2012. The NIH FAQ can be found at this link: The information provided is current as of March 27, 2018 and is subject to updates.

Other Public Resources and Research